INSIGHT PROVIDER
Top 5%
Xinyao (Criss) Wang

Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)

944
Insights
314.6k
Views
426
Followers
China Health Care Equity Bottom-Up Thematic (Sector/Industry)
Refresh
15 Apr 2024 08:57

Escalation of Israel-Hamas War - Here's How Investors Should Position Themselves in Dramatic Changes

Iran's attack on Israel is just the start.The escalation of Middle East conflict seems inevitable. In 24H2, we may see a series of "beyond...

Share
15 Apr 2024 08:55

Pre-IPO Sichuan Baicha Baidao Industrial (PHIP Updates) - Some Points Worth the Attention

​Baicha Baidao's profit model faces challenges due to rapid expansion, leading to declining profitability/market attractiveness, potentially...

Share
14 Apr 2024 16:11

China Healthcare Weekly (Apr14)- Shanghai Shyndec Pharma,Innovative Drug Policy,Ultra Long-Term Bond

​China will issue special treasury bonds for healthcare.New policy boosts hope for innovative drugs.Horizontal competition in Taiji and Shanghai...

Share
11 Apr 2024 08:55

China Shineway Pharmaceutical (2877.HK) - 24H1 Looks Challenging, but Things Get Better in 24H2

Shineway’s 23H2 performance was disappointing due to formula granule VBP and anti-corruption campaign. Favorable reimbursement policy helps to...

Share
10 Apr 2024 08:55

China TCM (570.HK) - Latest Updates on Privatization and the Potential Merger with Taiji Group

The privatization is highly likely to succeed. It's not wise for investors to bet against privatization.Taiji's high-level personnel changes...

Share
x